Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 853 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AMG 853 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AMG 853 | DRUG | AMG 853 5 mg (BID) |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Males or females 18 to 65 years of age * Percent of predicted FEV1 ≥ 50% and ≤ 80% * At least 12% reversibility over pre-bronchodilator FEV1 * Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone or equivalent. * Ongoing asthma symptoms with ACQ score ≥ 1.5 points ...
AMG 853 is an investigational small molecule being studied for the treatment of asthma. It has been evaluated in clinical trials involving adults and adolescents with inadequately controlled asthma, as well as in healthy volunteers for pharmacokinetic studies. The drug is being developed by Amgen Inc. and is currently in Phase 2 clinical development.
AMG 853 is a small molecule developed by Amgen Inc. for respiratory conditions, specifically asthma. While the specific molecular target has not been disclosed in the available information, the drug is being investigated for its ability to treat asthma in clinical trials. It is currently in Phase 2 development.
AMG 853 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The drug is an investigational small molecule intended for the treatment of asthma and has completed Phase 2 clinical trials.
AMG 853 is in Phase 2 clinical development for asthma. It has completed two Phase 1 trials and one Phase 2 trial, all of which are finished. The drug is not yet approved and remains investigational, with no active trials currently ongoing.
AMG 853 has been studied in three completed clinical trials. NCT01018550 was a Phase 2 study in 397 adults with inadequately controlled asthma. NCT01124279 was a Phase 1 pharmacokinetic study in 43 healthy volunteers. NCT01137565 was a Phase 1 safety and pharmacodynamics study in 23 adolescents with asthma.
AMG 853 is a distinct investigational small molecule developed by Amgen Inc. for asthma. No alternative names have been reported for this drug. It is being studied as a potential treatment for asthma and has completed clinical trials, but it is not yet approved by regulatory authorities.